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Impaired lymphocyte trafficking in 
mice deficient in the kinase activity 
of PKN1
Rana Mashud1, Akira Nomachi2, Akihide Hayakawa3, Koji Kubouchi1, Sally Danno1, Takako 
Hirata4, Kazuhiko Matsuo5, Takashi Nakayama5, Ryosuke Satoh6, Reiko Sugiura6, Manabu 
Abe7, Kenji Sakimura7, Shigeharu Wakana  8, Hiroyuki Ohsaki9, Shingo Kamoshida9 & 
Hideyuki Mukai1,10
Knock-in mice lacking PKN1 kinase activity were generated by introducing a T778A point mutation 
in the catalytic domain. PKN1[T778A] mutant mice developed to adulthood without apparent 
external abnormalities, but exhibited lower T and B lymphocyte counts in the peripheral blood than 
those of wild-type (WT) mice. T and B cell development proceeded in an apparently normal fashion 
in bone marrow and thymus of PKN1[T778A] mice, however, the number of T and B cell counts were 
significantly higher in the lymph nodes and spleen of mutant mice in those of WT mice. After transfusion 
into WT recipients, EGFP-labelled PKN1[T778A] donor lymphocytes were significantly less abundant in 
the peripheral circulation and more abundant in the spleen and lymph nodes of recipient mice compared 
with EGFP-labelled WT donor lymphocytes, likely reflecting lymphocyte sequestration in the spleen 
and lymph nodes in a cell-autonomous fashion. PKN1[T778A] lymphocytes showed significantly lower 
chemotaxis towards chemokines and sphingosine 1-phosphate (S1P) than WT cells in vitro. The biggest 
migration defect was observed in response to S1P, which is essential for lymphocyte egress from 
secondary lymphoid organs. These results reveal a novel role of PKN1 in lymphocyte migration and 
localization.
Protein kinase N (PKN) is a serine/threonine protein kinase with a catalytic domain homologous to that of protein 
kinase C (PKC) and a unique regulatory region containing antiparallel coiled-coil (ACC) domains1, 2. PKN1, also 
known as PKNα or PRK1, is one of three PKN isoforms derived from different genes in mammals. PKN1 was first 
described as a fatty acid- and phospholipid-activated serine/threonine protein kinase and a protease-activated 
protein kinase3, 4. PKN1 is also an effector protein kinase of Rho family GTPases, such as RhoA, RhoB, RhoC, 
and Rac, in mammalian tissues1, 5–11. Various PKN1 functions have been revealed using cell culture experiments; 
for example, it is involved in the regulation of cytoskeletal reorganization12, 13, cell adhesion14, 15, cell-cycle regula-
tion16–18, and tumorigenesis19, 20. At the organismal level, PKN1 is ubiquitously expressed in various mammalian 
tissues, but is particularly highly expressed in lymphoid organs, suggesting major roles in lymphoid tissues1. Yasui 
et al. have reported that PKN1 knockout (KO) mice appear normal and do not exhibit defects in lymphocyte 
development in PKN1 KO mice within 12 weeks of age21. However, they also reported that germinal centers form 
spontaneously in the spleen at more than 30 weeks of age in PKN1 KO mice, even in the absence of immunization 
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or infection, and these mice eventually develop an autoimmune-like disease characterized by autoantibody pro-
duction and glomerulonephritis21.
PKN1 functions as an intracellular signalling molecule, in some cases independent of phosphorylation activ-
ity, e.g., it activates phospholipase D122 and acts as a scaffold protein for the p38γ MAPK signalling pathway23. 
Therefore, to explore the role of the phosphorylation activity of PKN1 in vivo, we generated knock-in mice 
expressing kinase-negative mutant of PKN1 by introducing a T778A point mutation in the activation loop of the 
catalytic domain. PKN1[T778A] mice grew to adulthood, without apparent external abnormalities, consistent 
with PKN1 KO mice reported previously21. However, PKN1[T778A] mice showed lymphopenia and the accumu-
lation of lymphocytes in secondary lymphoid organs. We discuss the mechanism underlying this phenomenon 
and the essential role of PKN1 in lymphocyte trafficking in vivo.
Results
Generation of PKN1 kinase-negative knock-in mice. Thr778 in the activation loop of the catalytic 
domain of mouse PKN1, corresponding to Thr774 of human PKN1, is critical for kinase activity, and an alanine 
mutation at this position results in a complete loss of kinase activity24. To investigate the physiological importance 
of PKN1 kinase activity, we generated a PKN1 kinase-negative knock-in mouse line by introducing the T778A 
mutation into the PKN1 gene. The knock-in vector was introduced into C57BL/6 embryonic stem (ES) cells by 
electroporation, and chimeric mice were generated from the recombinant ES clone. The PKN1 heterozygous 
knock-in (PKN1 T778A/+) mouse line was established after removing neo (the neomycin-resistance gene) by 
crosses with EIIα-Cre mice25 expressing Cre recombinase in the early embryo (Fig. 1a–c). The genotypic distri-
bution of the offspring obtained after crossing heterozygous mice was consistent with Mendelian inheritance. 
PKN1 homozygous knock-in (PKN1 T778A/T778A, hereinafter referred to as “PKN1[T778A]”) mice developed 
into fertile adults and were morphologically indistinguishable from their wild-type (WT) counterparts (data not 
shown). Immunoblot analyses of tissue homogenates revealed that PKN1 in PKN1[T778A] mice were approx-
imately 1/4 to 1/2 those in WT mice (Fig. 1d), with some variation among tissues. A real-time PCR analysis 
of PKN1 mRNA showed comparable PKN1 transcript levels in mutant and WT mice (Fig. 1e), suggesting that 
mutant PKN1 is unstable at the protein level in vivo. Immunoprecipitates from the lysate of the PKN1[T778A] 
mouse spleen, examined using an anti-PKN1 antibody, did not show any autophosphorylation activity, while 
PKN1 levels were equal in the precipitates from PKN1[T778A] tissues and WT counterparts (Fig. 1f). These 
results verify that PKN1[T778A] mice completely lacked PKN1 kinase activity, as expected. Therefore, the protein 
expression of T778A PKN1 may be reduced in vivo due to the instability of the unphosphorylated form of PKN1. 
This hypothesis is supported by a previous analysis indicating that PKN1 expression is reduced in ES cells lacking 
PDK1, but PKN1 mRNA exhibits identical expression levels in PDK1 null and PDK1+/+ ES cells26. The expres-
sion levels of other isoforms of PKNs, such as PKN2 and PKN3, were comparable to those of WT counterparts 
(Fig. 1g).
PKN1 [T778A] mice exhibit normal lymphoid development, but decreased peripheral blood 
lymphocytes. Based on peripheral blood analyses, the white blood cell count was significantly lower in 
PKN1[T778A] mice than in PKN1 T778A/+ or WT mice, despite comparable red blood cell and platelet counts 
(Fig. 2a). Differential white blood cell counts revealed that the absolute number of lymphocytes in PKN1[T778A] 
mice was approximately half that in PKN1 T778A/+ or WT mice, whereas the absolute numbers of eosino-
phils and neutrophils in PKN1[T778A] mice were comparable to those in WT mice (Fig. 2b and Table 1). 
Flow cytometric analyses of peripheral circulating white blood cells revealed that both T and B lymphocytes in 
PKN1[T778A] mice were almost half those in WT mice, and both CD4 (+) and CD8 (+) T cells were signifi-
cantly reduced in PKN1[T778A] mice (Fig. 2c). Next, T cell development in the thymus and B cell development 
in the bone marrow were examined based on the expression patterns of cell surface antigens. Flow cytometric 
analyses of T and B cells in both organs of 8-week-old PKN1[T778A] mice revealed the presence of approximately 
normal percentages of various thymic, T, and B lineage cell populations; the numbers of cells in these organs were 
similar to those of WT mice (Fig. 3a and b). Serum level of IgA, IgM, and IgG did not show significant difference 
between WT and PKN1[T778A] mice, suggesting that the overall normal production of immunoglobulin, with-
out class switch abnormalities in PKN1[T778A] mice (Supplementary Fig. 1). These findings indicate that the 
T778A mutation in PKN1 does not have a marked effect on overall lymphocyte development.
Lymphocytes are sequestered in secondary lymphoid organs. Lymphocyte counts were normal in 
the thymus and bone marrow and decreased in the peripheral blood; however, the numbers of lymphocytes in the 
spleen and lymph nodes, i.e., secondary lymphoid organs, in 8-week-old PKN1[T778A] mice were significantly 
elevated compared with those in WT mice (Fig. 3c and d). There was no significant change in the T-to-B cell ratio, 
and most lymphocyte subsets accumulated in both the lymph nodes and spleen of PKN1[T778A] mice, suggest-
ing that lymphocytes are generally sequestered to secondary lymphoid organs in PKN1[T778A] mice. However, 
hematoxylin & eosin staining of lymph node and spleen sections from PKN1[T778A] mice did not show signif-
icant structural abnormalities, and immunohistochemical staining revealed similar segregation of T and B cells 
and macrophage distribution in both organs of PKN1[T778A] mice and WT mice (Fig. 4).
PKN1 has been suggested to inhibit PDK1-mediated activation of PKB/Akt in cells21, 27. Since Akt influences 
cell survival pathways by inhibiting apoptotic processes; the inhibition of PKN1 might promote the overall sur-
vival of lymphocytes, leading to their accumulation in secondary lymphoid organs. Therefore, we performed a cell 
survival assay to examine whether PKN1[T778A] mutant lymphocytes exhibit reduced cell death. Splenic lym-
phocytes were incubated in complete RPMI 1640 medium containing 10% fetal bovine serum (FBS) for various 
times and were subjected to flow cytometry using Annexin V-allophycocyanin (APC) and 7-aminoactinomycin 
D (AAD). As shown in Fig. 5, PKN1[T778A] mutant lymphocytes did not exhibit increased survival, but rather 
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Figure 1. Generation of PKN1[T778A] mice. (a) Schematic diagram of the PKN1 genomic DNA, targeting 
vector, and disrupted gene. The targeting vector and a partial map of PKN1 locus before (wt) and after (mt) 
homologous recombination in embryonic stem cells, and after further deletion of the neomycin resistance 
cassette (ki) by Cre-mediated recombination. Positions of loxP sites are designated by black triangles. Crosses 
with heterozygous mice generated homozygous PKN1 kinase-negative knock-in (PKN1[T778A]) mice. Exons 
are denoted by black boxes. Positions of the genomic DNA probes (A and B) used for Southern blotting and 
the primers used for discrimination between wt and ki (N1-geF and N1-geR) are indicated. A, probe A; B, 
probe B; Cre, P1 bacteriophage cyclization recombination; loxP, locus of X-over in P1; E, exon; Neor, neomycin-
resistance gene; MC1 pro, MC1 promoter; DT-A, Diphtheria toxin A; *, T778A mutation. (b) Southern 
blot results for representative littermates (F2 mice) obtained by crossing F1 mice with WT mice are shown. 
Genomic DNA of F2 mice was digested with NheI and NotI, probed with probe A on the left, and digested 
with BamHI and HindIII, probed with probe B on the right. (c) PCR genotyping. Representative results are 
shown for discrimination between wt and ki allele (lacking the Neo cassette). (d) Whole-cell lysates of each 
tissue from WT and PKN1[T778A] mice were resolved by SDS-PAGE and subjected to immunoblot analyses 
using αC6 for PKN1 detection. Coomassie Brilliant Blue (CBB)-stained PVDF membrane is shown (lower 
panel). (e) PKN1 expression in the thymus, lymph nodes, and spleen of WT and PKN1[T778A] mice was 
measured by RT-qPCR. Data represent fold changes in PKN1 gene expression in [T778A] mice normalized to 
GAPDH relative to expression in WT mice. Data were analysed with unpaired t-tests. NS, not significant. (f) 
Immunoprecipitation and kinase assay of PKN1. Immunoblotting results using αC6 are shown in the upper 
panel, and autoradiography results are shown in the lower panel. (g) Expression of PKN2 and PKN3, and 
phosphorylation levels of PKN2 at Thr815 are shown. For raw gel data see Supplementary Fig. 3.
www.nature.com/scientificreports/
4SCIentIfIC RepORtS | 7: 7663  | DOI:10.1038/s41598-017-07936-9
Figure 2. Peripheral blood counts. (a) Peripheral blood count. (b) Differential white blood cell count. 
(c) Cell population analysis of the peripheral blood. The numbers of total cells and indicated subsets of 
lymphocytes in the peripheral blood were determined in WT (open bars) and PKN1[T778A] mice (closed 
bars). Peripheral blood was obtained from 8-week-old mice. Naïve CD4, CD4+CD45RBhiCD44lo; Memory 
CD4, CD4+CD45RBloCD44hi; Naïve CD8, CD8+CD45RBhiCD44lo; Memory CD8, CD8+CD44hi; Neutrophils, 








PKN1+/+ 8.1 ± 0.3 2.6 ± 0.5 7.1 ± 0.4
PKN1 T778A/+ 7.8 ± 0.5 2.5 ± 0.3 6.7 ± 0.4
PKN1 T778A/T778A 4.8 ± 0.2 2.5 ± 0.2 6.1 ± 0.5
Table 1. White blood cell cellularity in the peripheral blood (absolute number) (mean ± SEM).
www.nature.com/scientificreports/
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were susceptible to apoptosis and cell death, for as yet unknown reasons. Therefore, the accumulation of lympho-
cytes in the spleen of PKN1[T778A] mice is not likely due to the anti-apoptotic tendency of lymphocytes.
Next, we examined whether the T778A mutation in PKN1 contributes to the aberrant distribution of lympho-
cytes in a cell-autonomous fashion using an adoptive transfer experiment. To prepare labelled donor lymphocytes 
for transfusion, enhanced green fluorescent protein gene (EGFP) was introduced to both WT and PKN1[T778A] 
mice by crosses with EGFP transgenic mice. EGFP-labelled splenic lymphocytes were isolated from individual 
donor mice and were injected into the tail veins of recipient WT mice. The numbers of transferred cells that 
migrated into the spleen and lymph nodes were determined 7 days after the transfusion. As shown in Fig. 6a and b, 
significantly more [T778A] mutant than WT T cells and B cells from donor mice were collected from both the 
spleen and lymph nodes of recipient mice. In contrast, significantly fewer [T778A] mutant than WT T cells and 
B cells from donor mice were collected from the peripheral blood of recipient mice at 72 hours after transfu-
sion (Fig. 6c), despite no difference in total peripheral blood lymphocytes (Fig. 6d). These results suggest that 
PKN1[T778A] mutant lymphocytes transfused into WT mice recapitulate the impaired trafficking observed in 
PKN1[T778A] mice in a cell-autonomous fashion.
[T778A] mutant lymphocytes exhibit defective migration toward chemokines and sphingosine 
1-phosphate (S1P). The lymphocyte distribution is mainly determined by migration to chemokines and the 
Figure 3. Lymphocyte cellularity of primary and secondary lymphoid organs. Cell population analysis in 
the bone marrow (a), thymus (b), spleen (c), and lymph nodes (d). The numbers of total cells and indicated 
subsets of white blood cells were determined in 8-week-old WT (open bars) and PKN1[T778A] mice (closed 
bars). The axillary and inguinal lymph nodes were used as peripheral lymph nodes for analysis. CD4 naïve, 
CD4+CD45RBhiCD44lo; CD4 memory, CD4+CD45RBloCD44hi; CD8 naïve, CD8+ CD45RBhiCD44lo; CD8 
memory, CD8+CD44hi; Pro-pre, B220+IgM−IgD−; IgD-, B220+IgM+IgD−; IgDlo, B220+IgM+IgDlo; Mature, 
B220+IgM+IgDhi; Granulo, Gr-1hi; Mono, Gr-1medCD11bhi; CD4SP imm, CD4+CD8−CD62LloCD69hi; 
CD4SP Mat, CD4+CD8−CD62LhiCD69lo; CD8SP Imm, CD4−CD8+CD62LloCD69hi; CD8SP 
Mat, CD4−CD8+CD62LhiCD69lo; DP, CD4+CD8+; DN1, Lin−Thy1.2+CD25−CD44+; DN2, 
Lin−Thy1.2+CD25+CD44+; DN3, Lin−Thy1.2+CD25+CD44−; DN4, Lin−Thy1.2+CD25−CD44−; Treg, 
CD4+CD25+; T1, AA4.1+B220+IgMhiIgDlo; T2, AA4.1+B220+IgM+IgDhi; FO, B220+ IgM+CD21intCD23hi; MZ, 
B220+IgM+CD21hiCD23lo. Data were analysed with unpaired t-tests. *P < 0.05, **P < 0.01, ***P < 0.001.
www.nature.com/scientificreports/
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small lipid mediator sphingosine 1-phosphate (S1P)28; accordingly, we examined the responses of PKN1 [T778A] 
lymphocytes to these factors in vitro. The chemokine family subset involved in the promotion of the organization 
and function of secondary lymphoid tissues is referred as homeostatic chemokines, including CC chemokine 
ligand CCL21 and CXC chemokine ligand CXCL13. These chemokines are important for the entry of lympho-
cytes into lymph nodes and the white pulp of the spleen. S1P is required for the egress of lymphocytes from 
secondary lymphoid organs28, 29. As shown in Fig. 7a and b, a chemotaxis assay revealed that the migration of 
[T778A] lymphocytes was mildly impaired toward CCL21 and CXCL13, and was severely impaired toward S1P. 
The severely impaired egress of PKN1[T778A] lymphocytes from secondary lymphoid organs (compared with 
the impairment of the entry of lymphocytes into the organs) may explain the PKN1[T778A] mouse phenotype. 
To examine whether the defective lymphocyte migration in PKN1[T778A] mice is caused at the level of cell sur-
face receptors of S1P, we analysed the expression level of S1PR1, an S1P receptor known to play a major role in 
the egress of lymphocytes, by flow cytometry. As shown in Fig. 7c, there was no significant difference in the cell 
surface expression levels of S1PR1 between PKN1[T778A] mutant and WT lymphocytes.
Discussion
The immune system exhibits a continuous steady state equilibrium of developing cells and effector cells of the 
lymphoid and myeloid lineages. Although it is estimated that ~70% of the body’s lymphocytes are in lymphoid tis-
sues and 2% are in the blood, lymphocytes equivalent to approximately the entire lymphocyte count in the whole 
body are trafficked between the blood and lymphoid tissues daily30, 31. Newly generated lymphocytes migrate 
from the bone marrow or thymus into the blood and travel to secondary lymphoid organs, such as the spleen and 
lymph nodes. Entry from the blood to lymphoid tissues involves a multistep cascade, including selectin-mediated 
cell rolling, followed by chemokine-triggered integrin activation, integrin-mediated adhesion, and transmigra-
tion across the endothelium32. After surveying the secondary lymphoid organs, T and B cells egress to the blood 
and lymph, migrating to other lymphoid organs and continuing surveillance. Egress from the secondary lym-
phoid organs has not been well-characterized, but some studies have suggested that the major driving force that 
mediates lymphocyte egress from lymphoid organs is the concentration differential of S1P between luminal and 
abluminal compartments via stimulation of the lymphocyte S1P receptor33–36. The lipid ligand S1P is ubiquitously 
synthesized, but is largely degraded in most tissues, resulting in low ligand levels in lymphoid tissues and higher 
concentrations in the blood and lymph35. The S1P receptor 1 (S1PR1), one of the five G protein-coupled S1P 
receptors, has been shown to control lymphocyte egress from the thymus37, 38, spleen37, 39, and lymph nodes37, 
based on S1PR1 deletion experiments. In this paper, we demonstrated the impaired trafficking of lymphocytes in 
PKN1[T778A] mice, while PKN1 was not essential for lymphocyte differentiation until at least 8 weeks of age. An 
in vitro chemotaxis analysis and adoptive transfer experiment indicated that the impairment is a PKN1[T778A] 
mutant lymphocyte cell-autonomous phenotype. PKN1[T778A] lymphocytes showed remarkably less migratory 
Figure 4. Histological analysis of secondary lymphoid organs. Representative observation from samples of 
lymph nodes and spleens of 9-week-old mice are shown. H&E, hematoxylin & eosin (H&E) staining; CD3, 
immunostaining for CD3; B220, immunostaining for B220/CD45R; MAC-2, immunostaining for MAC-2/
Galectin-3. Scale bar: 50 μm.
www.nature.com/scientificreports/
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activity toward S1P than that of WT lymphocytes. Therefore, PKN1[T778A] mutant lymphocytes may be less 
competent to exit from secondary lymphoid organs to the blood and lymph, leading to the accumulation of lym-
phocytes in secondary lymphoid organs and a decrease in lymphocytes in the peripheral blood of PKN1[T778A] 
mice. The [T778A] mutant lymphocytes also showed mildly reduced migratory activity toward CCL21 and 
CXCL13, critical chemokines for the entry of lymphocytes into secondary lymphoid organs; however, predomi-
nant suppression of egress from secondary lymphoid organs seems to result in lymphocyte accumulation in these 
organs. This inference is supported by a previous study indicating that S1PR1 in lymphocytes controls lymph node 
egress by overcoming retention signals mediated by CCR7 and additional Gαi-coupled receptors40. However, it is 
unlikely that impaired lymphocyte trafficking in PKN1[T778A] mice can be totally attributed to the lack of S1PR1 
signalling in lymphocytes, based on the following observations: (i) Although the inhibitory effects of S1PR1 
receptor signalling on the egress of lymphocytes from secondary lymphoid organs have been established37–39, 
its effects on recirculating lymphocytes in the spleen are less clear. FTY720 (fingolimod) is a S1P analogue with 
Figure 5. Survival assay of splenic lymphocytes from WT and PKN1[T778A] mice. Viability of lymphocytes 
were evaluated by flow cytometry with Annexin V-APC and 7-AAD using BD Accuri flow cytometer and 
Accuri C6 Software. (a) Representative dot plots at the indicated time points are shown. (b) Viability was 
evaluated as the percentage of cells that were negative for both Annexin V-APC and 7-AAD. (c) The apoptotic 
cell percentage was quantified from cells that were positive for Annexin V-APC and negative for 7-AAD. Data 
were analysed with paired t-tests. *P < 0.05. **P < 0.01.
www.nature.com/scientificreports/
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an antagonistic effect on S1PR1 by inducing proteasome-mediated degradation of S1PR141, creating a pharma-
cological S1PR1-null state in lymphocytes. The single administration of FTY720 sequesters circulating mature 
lymphocytes in peripheral lymph nodes and thereby increases the number of lymphocytes in lymph nodes and 
decreases the number in peripheral blood as well as in the spleen in rats42 and mice43, 44. However, PKN1[T778A] 
lymphocytes accumulated in the spleen as well as in lymph nodes (Fig. 3c). (ii) Analyses of S1PR1-deficient fetal 
liver chimeras37 and T cell-specific S1PR1 knockout mice45 have revealed peripheral lymphocyte deficiencies and 
the thymic accumulation of mature CD4 and CD8 single-positive T cells at the same time. This mature thymo-
cyte accumulation has also been observed in mice treated with FTY72046. However, PKN1[T778A] mice did not 
exhibit the accumulation of CD4 and CD8 single-positive T cells in the thymus (Fig. 3b). Other isoforms of S1P 
receptors might also play roles in impaired lymphocyte trafficking in PKN1[T778A] mice. For instance, S1PR2 
may be a candidate, since it has been reported to mediate the confinement of B cells and follicular T helper (Tfh) 
cells to lymph node germinal centers47, 48.
The cell-surface expression level of S1PR1 did not differ significantly between [T778A] and WT lympho-
cytes (Fig. 7c); therefore, the PKN1[T778A] mutation seems to impair a signalling step downstream of the S1P 
Figure 6. Adoptive transfer experiments. Percentage of EGFP-positive donor lymphocytes collected from the 
WT recipient spleen (a), lymph nodes (b), and peripheral blood (c). (d) Total PBMC count. Peripheral blood 
was isolated at the indicated time points. Genotypes of donors are labelled at the bottom. Data were analysed 
with paired t-tests. *P < 0.05. **P < 0.01. ***P < 0.001. NS, not significant.
www.nature.com/scientificreports/
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receptor in lymphocytes. What is the mechanism underlying defective lymphocyte trafficking induced by the 
PKN1[T778A] mutation? PKN1 has important roles in cell migration and invasion in various adherent cell lines, 
including prostate adenocarcinoma cell lines, such as PC-3 and LNCaP stimulated by thromboxane and andro-
gen49–51, androgen-independent prostate tumour cell lines, such as PC-3M-luc2 and Du14552, the triple-negative 
breast cancer cell line MDA-MB-23152, the bladder tumour cell line 563753, and human aortic smooth muscle cells 
stimulated by monocyte chemotactic protein (MCP)-154. In these cases, PKN1 has been suggested to be involved 
in processes downstream of Rho or Rac GTPases, major molecular switches of cell migration and cytoskeletal reg-
ulation in these cells. Rho and Rac GTPases are also reported to play major roles in lymphocyte migration as fol-
lows. (i) RhoA and Rac1 influence chemokine-induced T-cell polarity, which is crucial for in vivo migration55–57. 
(ii) Chemokines, such as CCL21, CXCL13, and CXCL12, bind to G-protein-coupled receptors, leading to the 
activation of Rho and Rac GTPases in B cells58–60. (iii) S1P binds to G-protein-coupled S1PR1, which activates the 
RhoA-specific guanine nucleotide exchange factor (GEF) Lsc (also known as ARHGEF1) and the Rac-specific 
GEF DOCK2, leading to the migration and egress of lymphocytes from lymph nodes61, 62. Indeed, T cells deficient 
in mDia1, an effector protein of Rho GTPases like PKN1, exhibit impaired egress from the thymus to secondary 
lymphoid organs, and reduced chemotaxis. Additionally, mDia1 KO mice develop lymphopenia, characterized 
by diminished T cell populations in lymphoid tissues, but develop without apparent abnormalities and B cell phe-
notypes, for unknown reasons63, 64. In our study, the migration activity of PKN1[T778A] lymphocytes was lower 
Figure 7. Chemotaxis of lymphocytes in vitro. Migration of CD4 (+) T cells, CD8 (+) T cells, and B cells from 
the spleens and lymph nodes of WT (open bars) and PKN1[T778A] (closed bars) mice toward the indicated 
chemokines (a) and S1P (b) was examined using a Transwell chamber. Data were analysed with unpaired t-
tests. *P < 0.05. **P < 0.01. ***P < 0.001. (c) Flow cytometric analysis of the surface expression of S1PR1 on 
T and B lymphocytes isolated from the spleen and lymph nodes. S1PR1 expression profiles were determined 
after gating cells based on CD3 or B220/CD45R expression patterns. The profiles shown in black (WT) and 
violet (PKN1[T778A]) indicate background staining using the isotype control antibody (IgG2A)-APC, and the 
profiles shown in blue (WT) and red (PKN1[T778A]) indicate staining with the anti S1PR1 antibody-APC.
www.nature.com/scientificreports/
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than that of WT cells when stimulated by chemokines (CCL21 for T cells, CXCL13 for B cells, and CXCL12 for 
T and B cells in Fig. 7a and Supplementary Fig. 2), although the magnitude of the decrease in migration activity 
was less than that observed in response to S1P stimulation (Fig. 7b). Therefore, it is likely that PKN1 is widely 
involved in chemokine- and S1P-induced lymphocyte migration downstream of Rho or Rac GTPase functions. 
PKN1[T778A] mice showed a characteristic set of trafficking abnormalities, i.e. deficiencies in both T and B 
cells in the peripheral blood, the accumulation of T and B cells in lymph nodes and the spleen, a lack of changes 
in primary lymphoid organs, and normal numbers of other hematopoietic cells, such as eosinophils, basophils, 
platelets, and red blood cells. The same set of phenotypes has not been observed in other genetically modified 
mice to date. Future analyses of PKN1[T778A] mice may unravel novel mechanisms of lymphocyte trafficking. 
PKN1 has been regarded as promising targets for the treatment of cancers52, 65, 66. Therefore, it would be beneficial 
to clarify the phenotype of PKN1[T778A] mice from the viewpoint of side effects by PKN1 inhibitor for thera-
peutic purpose.
Materials and Methods
Animals. For all studies in this manuscript, mice were compared to littermates or controls, and all were 
Specific Pathogen Free (SPF). This study was approved by the Institutional Animal Care and Use Committee and 
carried out according to the Kobe University and Kindai University animal experimentation regulations.
Generation of PKN1 kinase-negative knock-in mice. A genomic fragment of the mouse PKN1 gene 
was isolated from mouse BAC library RPCI-23-394G23 (C57BL/6). The targeting vector for PKN1 contained a 
~8 kbp SalI–NotI DNA fragment including exon 10–22 of PKN1, pgk-1 promoter-driven neomycin phospho-
transferase gene (pgk-neo) flanked by two Cre recognition target (loxP) sites, and a ~4 kbp SwaI/XhoI DNA 
fragment and followed by the diphtheria toxin (DT) gene for negative selection (Fig. 1a). The kinase-negative 
knock-in vector was constructed by introducing this targeting vector with the point mutation encoding ala-
nine instead of threonine-778 and insertion of oligonucleotide encoding FLAG peptide to the 3′-terminal of 
the coding region of PKN1 in exon 22 (Fig. 1). We used the C57BL/6-derived ES cell line RENKA67 for the gene 
targeting. The ES cells were cultured as described68. The targeting vector was linearized and electroporated into 
ES cells by using Gene Pulser Xcell (Bio-Rad, Hercules, CA). G-418 selection (175 μg/ml) was started 36–48 hours 
after electroporation and continued for 1 week. The recombinant ES cell clones were identified by Southern blot 
analyses, and were injected into 8-cell-stage embryos of ICR mice. The embryos were cultured to blastocysts and 
transferred to the uterus of pseudopregnant ICR mice. The resultant chimeric mice were mated with C57BL/6 
mice and the F1 mice were screened by Southern blot to establish the mutant PKN1 F1 mouse line. The mutant 
F1 mice were crossed with the transgenic strain expressing a Cre recombinase gene under the direction of EIIα 
promoter25 to remove neomycin resistant gene (neo) cassette and later isolated PKN1 mutant strain lacking Cre 
gene, and were backcrossed at least 10 times into the Charles River C57BL/6N background before phenotypic 
analysis. The resultant PKN1[T778A] mutant mice were born at a frequency expected for Mendelian inheritance.
Genotyping. Genomic DNA was isolated from ES cells and mouse tail snips by standard techniques and 
subjected to Southern blot analysis and PCR analysis for identification. Southern blot analysis was performed 
using genomic DNA digested with NheI/NotI and BamHI/HindIII probed with probe A and probe B, respec-
tively, as indicated in the Fig. 1a. Wild type (“wt” in Fig. 1a) and mutant (“mt” in Fig. 1a) alleles containing Neo 
cassettes are indicated by the presence of a 15 kbp versus 11.5 kbp DNA fragment for probing with probe A, and 
a 12.5 kbp versus 5 kbp DNA fragment for probing with probe B (Fig. 1b). Genotyping of mouse tail, for discrim-
ination of wt and mutant lacking Neo cassette (“ki” in Fig. 1a) was performed using the PCR primers N1-geF 
(5′-GCCTCTGTGTGCATCTGG–3′), N1-geR (5′-CCTTCTACCCACACGGCC-3′), yielding PCR products of 
170 bp (wt) and 270 bp (ki) (Fig. 1c). Reaction conditions were as follows: 96 °C for 5 min for 1 cycle, and 96 °C for 
1 min, 63 °C for 1 min, 72 °C for 1 min for 35 cycles, and 72 °C for 5 min for 1 cycle.
RT-qPCR (Reverse transcription quantitative polymerase chain reaction). Total RNA of mouse 
thymus, spleen and lymph node were isolated by using an RNeasy mini kit (QIAGEN), according to the man-
ufacturer’s instructions. The cDNAs were synthesized using ReverTra Ace qPCR RT Master Mix (TOYOBO) 
according to the manufacturer’s protocols. qPCR was performed (45 cycles of 10 seconds at 95 °C, 10 seconds at 
60 °C, and 10 seconds at 72 °C) with Thunderbird SYBR qPCR Mix (TOYOBO) using the LightCycler480 System 
(Roche). The sense primer for PKN1 was (5′-TGCTCTATGAGATGTTGGTTGGA-3′) and the antisense primer 
was 5′-CAGACAGGAAGCGGGGATAG-3′). Expression of GAPDH was used as an endogenous control. ΔΔCt 
method was used to determine relative fold expression of mRNA.
Antibodies. The polyclonal antibodies αN2 and αC6 for PKN1 were prepared as described69. The polyclonal 
antibody αNUS for detection of PKN3 was prepared as described70. Anti PRK2 antibody for PKN2 was pur-
chased from BD Transduction Laboratories, and anti phospho-PRK1 (Thr774)/PRK2 (Thr816) antibody was 
from Cell Signaling Technology. Annexin V-APC and 7-ADD were purchased from BD Biosciences. The mAbs 
used for flow cytometric analyses for cell surface antigens were purchased from BD Biosciences, eBioscience or 
BioLegend. Anti-mouse EDG-1/S1PR1-APC MAb (Clone 713412) and Rat IgG2A-APC Isotype Control were 
purchased from R&D Systems and used for S1PR1 receptor assay. Anti CD3 rabbit monoclonal antibody (clone 
SP7; Abcam), an anti B220/CD45R rat monoclonal antibody (clone RA3-6B2; Abcam) and an anti MAC-2/
Galectin-3 rat monoclonal antibody (clone M3/38; Cedarlane) were used for immunohistochemical analysis.
Immunoblot analysis. Mouse organs and cells were lysed in SDS-sample buffer, boiled, and were subjected 
to 6–10% SDS-PAGE and separated products were subsequently transferred to a polyvinylidene difluoride mem-
brane. The membrane was then blocked with TBS (20 mM Tris/HCl at pH 7.5, 137 mM NaCl) containing 0.05% 
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Triton X-100 (TBS-T) and 5% normal goat serum or Blocking One (nacalai tesque) for 1 hour at room tempera-
ture. The membrane was then incubated in TBS-T and the primary antibody for 1 hour at room temperature or 
for O/N at 4 °C. The membrane was washed three times (5 min each time) in TBS-T before incubating the blot in 
TBS-T containing the secondary antibody conjugated to horseradish peroxidase at 1:2000–1:10,000 dilution for 
45 min. After this incubation, the membrane was subjected to three 10 min washes in TBS-T. Blots were devel-
oped by the enhanced chemiluminescence method.
Immunoprecipitation and kinase assay. Spleens were isolated from WT and PKN1[T778A] mice and 
homogenized in homogenate buffer (50 mM Tris/HCl at pH 7.5, 150 mM NaCl, 1 mM EDTA, 3 mM MgCl2, 1 mM 
DTT, 1 mM PMSF, 5 μg/ml leupeptin, 1 mM NaF, 1% NP-40). After centrifugation at 13,000 x g for 30 min, cleared 
lysates were incubated with αN2 at 4 °C for 2 hours, and the protein A-Sepharose (GE Healthcare) was added 
and incubated for further 30 min. The resulting immunoprecipitates were subjected to in vitro kinase assay and 
immunoblot analysis using αC6. For autophosphorylation reaction, the immunoprecipitates were incubated in 
25 μl reaction mixture (20 mM Tris–HCl, pH 7.5, 4 mM MgCl2, 100 μM ATP, 18.5 KBq [γ-32P]ATP) at 30 °C. After 
5 min, the reaction was stopped by addition of SDS sample buffer and boiled for 5 min. A 20 μl aliquot of reaction 
mixture was subjected to SDS–PAGE. The gel was fixed, dried, and subjected to autoradiography using BAS2000 
imaging analyzer (Fuji film).
Peripheral blood count. Peripheral blood of mice was collected from the retro-orbital venous plexus, and 
measured by an automatic hamatology analyzer (ADVIA120, SIEMENS) and also manually using hemocytom-
eter for Fig. 2 and Table 1.
Flow cytometry. Cell suspensions were prepared from bone marrow and spleen were treated with 1 x ACK 
buffer (150 mM NH4Cl, 10 mM KHCO3, 1 mM EDTA) to remove red blood cells, washed, and incubated with anti 
CD16/CD32 (BD Fc block) to block binding of conjugated antibodies to FcγR. Cell suspensions from thymus and 
lymph nodes were directly incubated with anti CD16/CD32 antibody.
After cells were labeled with appropriate primary antibodies for 30 min on ice and fixed in 1% paraformalde-
hyde in PBS. They were subjected to flow cytometry using FACSCalibur or Accuri (both from BD Biosciences) 
with FlowJo (FlowJo, LLC) or FCS Express 6 (De Novo Software) to determine the fraction of each subset. The 
surface expression of S1PR1 was evaluated using flow cytometry with anti-S1PR1-APC antibody. Staining with 
S1PR1 antibody was performed in the presence of fatty acid–free BSA (Sigma-Aldrich).
In vitro cell survival assay. Spleens were dissected out after decapitation of 7- to 9-week-old mice under 
anesthesia and shedding of circulating blood. Erythrocytes were lysed by 1 x ACK buffer, and isolated lympho-
cytes were suspended in MACS buffer (PBS containing 0.5% fatty acid-free BSA and 2 mM EDTA). One million 
of isolated splenic lymphocytes were incubated with RPMI 1640 containing 2 mM glutamine, 1% Penicillin G/
Streptomycin, and 10% fetal bovine serum in a 3.5 cm dish at 37 °C in 5% CO2 chamber. After 5, 10, and 24 hours, 
cells were washed and incubated with 7-AAD and Annexin V-APC for 15 min at room temperature. Cells were 
subjected to flow cytometry (BD Accuri), and those found positive for Annexin V and negative for 7-AAD were 
quantified as “apoptotic cells”, and those found negative for both Annexin V and 7-AAD were quantified as “via-
ble cells”.
Adoptive transfer. Transgenic mouse strain expressing EGFP under the control of CAG promoter was pro-
vided from Kumamoto university (CARD ID 2045). EGFP gene was introduced into WT and PKN1[T778A] 
mice by intercrossing of these mice with the EGFP transgenic mice. After anesthesia, 7- to 9-week-old EGFP 
and EGFP;PKN1[T778A] mice were decapitated and spleens were dissected out, followed by isolation of splenic 
lymphocytes with the aid of 1 x ACK buffer and MACS buffer as described in “in vitro cell survival assay” section. 
Isolated donor lymphocytes from EGFP and EGFP;PKN1[T778A] mice were suspended in Hank’s Balanced Salt 
Solution (HBSS), and 5 × 107 lymphocytes from each mouse were transfused into individual WT recipient mouse 
through tail vein, respectively. One hour after transfusion, ~50 μl of blood was collected from tail vein of each 
recipient mice. Peripheral Blood Mono nuclear Cells (PBMCs) were quantified using Turk’s solution, which was 
followed by flow cytometry (BD Accuri) with anti CD3-APC (for T lymphocyte) and anti B220/CD45R-APC (for 
B lymphocyte) antibodies. After gating through FL4 filter for APC, the percentage of EGFP-positive lymphocyte 
population was quantified using FL1 filter in recipient mice. Seventy-two hours after transfusion the same pro-
cedures were repeated. On the 7th day, recipient WT mice were sacrificed, and spleen and inguinal lymph nodes 
were dissected out, followed by lymphocyte isolation. Isolated lymphocytes were subjected to flow cytometry as 
described above to quantify the percentage of EGFP-positive lymphocyte population.
Histological analysis. Spleen and lymph nodes from 9-week-old mice were fixed in 4% paraformaldehyde 
and embedded in paraffin wax for histological analysis. Three-μm sections were processed after deparaffinization. 
The sections were stained with hematoxylin and eosin solution. Immunostaining for CD3, B220/CD45R and 
MAC-2/Galectin-3 was performed using the Universal Immunoenzyme Polymer method (Nichirei Bioscience) 
with an anti-CD3 rabbit monoclonal antibody, an anti-B220/CD45R rat monoclonal antibody, and an anti 
MAC-2/Galectin-3 rat monoclonal antibody, respectively. The signal was developed with a diaminobenzidine 
solution (Dako). HE-stained sections and immunostained sections were recorded by a BX-51 light microscope 
(Olympus).
In vitro migration assay. CCL21 and CXCL13 were purchased from R&D Systems. S1P was purchased 
from Sigma. In vitro migration assay was conducted using 96-well chemoTx chamber with 5-μm pore inserts 
(Neuroprobe) as described previously71. In brief, single cells prepared from mouse spleen or lymph nodes were 
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suspended at 8 × 106/ml in RPMI 1640 containing 1 mg/ml BSA and 20 mM HEPES (pH 7.4), and applied to 
upper wells (25 μl/well). The same medium without or with CCL21, CXCL13, or S1P at indicated concentrations 
was applied to lower wells (29 μl/well). After 1 h at 37 °C, the content of each lower well was transferred to a poly-
propylene pointed-bottom tube. The cells were pelleted by centrifugation at 200 × g for 5 min, resuspended in 
0.1% BSA in PBS, and stained with APC-Cy7-labeled anti-mouse CD4, PerCP-Cy5.5-labeled anti-mouse CD8, 
and FITC-labeled anti-mouse CD19. After washing, cells were analyzed on a FACSFortessa (BD Biosciences) and 
analyzed with FlowJo (FlowJo, LLC). All assays were done in duplicate.
Statistical analysis. All experiments were performed independently in at least triplicate and a statistical 
significance was calculated by Student’s unpaired t-test and Student’s paired t-test to examine the differences 
between the two groups of data. A p value < 0.05 was considered significant. Data displayed in the figures and text 
represent mean ± standard error (SEM) of representative experiments unless otherwise stated.
Data availability. The datasets generated during and/or analysed during the current study are available from 
the corresponding author on reasonable request.
References
 1. Mukai, H. The structure and function of PKN, a protein kinase having a catalytic domain homologous to that of PKC. J Biochem. 
133, 17–27 (2003).
 2. Maesaki, R. et al. The structural basis of Rho effector recognition revealed by the crystal structure of human RhoA complexed with 
the effector domain of PKN/PRK1. Mol Cell. 4, 793–803 (1999).
 3. Mukai, H. et al. Activation of PKN, a novel 120-kDa protein kinase with leucine zipper-like sequences, by unsaturated fatty acids and 
by limited proteolysis. Biochem Biophys Res Commun. 204, 348–356 (1994).
 4. Peng, B., Morrice, N. A., Groenen, L. C. & Wettenhall, R. E. Phosphorylation events associated with different states of activation of 
a hepatic cardiolipin/protease-activated protein kinase. Structural identity to the protein kinase N-type protein kinases. J Biol Chem. 
271, 32233–32240 (1996).
 5. Amano, M. et al. Identification of a putative target for Rho as the serine-threonine kinase protein kinase N. Science. 271, 648–650 
(1996).
 6. Watanabe, G. et al. Protein kinase N (PKN) and PKN-related protein rhophilin as targets of small GTPase Rho. Science. 271, 
645–648 (1996).
 7. Shibata, H. et al. Characterization of the interaction between RhoA and the amino-terminal region of PKN. FEBS Lett. 385, 221–224 
(1996).
 8. Hutchinson, C. L., Lowe, P. N., McLaughlin, S. H., Mott, H. R. & Owen, D. Differential binding of RhoA, RhoB, and RhoC to protein 
kinase C-related kinase (PRK) isoforms PRK1, PRK2, and PRK3: PRKs have the highest affinity for RhoB. Biochemistry. 52, 
7999–8011 (2013).
 9. Torbett, N. E., Casamassima, A. & Parker, P. J. Hyperosmotic-induced protein kinase N 1 activation in a vesicular compartment is 
dependent upon Rac1 and 3-phosphoinositide-dependent kinase 1. J Biol Chem. 278, 32344–32351 (2003).
 10. Owen, D. et al. Molecular dissection of the interaction between the small G proteins Rac1 and RhoA and protein kinase C-related 
kinase 1 (PRK1). J Biol Chem. 278, 50578–50587 (2003).
 11. Flynn, P., Mellor, H., Palmer, R., Panayotou, G. & Parker, P. J. Multiple interactions of PRK1 with RhoA. Functional assignment of 
the Hr1 repeat motif. J Biol Chem. 273, 2698–2705 (1998).
 12. Mukai, H. et al. Interaction of PKN with alpha-actinin. J Biol Chem. 272, 4740–4746 (1997).
 13. Vincent, S. & Settleman, J. The PRK2 kinase is a potential effector target of both Rho and Rac GTPases and regulates actin 
cytoskeletal organization. Mol Cell Biol. 17, 2247–2256 (1997).
 14. Calautti, E. et al. Fyn tyrosine kinase is a downstream mediator of Rho/PRK2 function in keratinocyte cell-cell adhesion. J Cell Biol. 
156, 137–148 (2002).
 15. Wallace, S. W., Magalhaes, A. & Hall, A. The Rho target PRK2 regulates apical junction formation in human bronchial epithelial 
cells. Mol Cell Biol. 31, 81–91 (2011).
 16. Isagawa, T., Takahashi, M., Kato, T. Jr., Mukai, H. & Ono, Y. Involvement of protein kinase PKN1 in G2/M delay caused by arsenite. 
Mol Carcinog. 43, 1–12 (2005).
 17. Schmidt, A., Durgan, J., Magalhaes, A. & Hall, A. Rho GTPases regulate PRK2/PKN2 to control entry into mitosis and exit from 
cytokinesis. EMBO J. 26, 1624–1636 (2007).
 18. Misaki, K. et al. PKN delays mitotic timing by inhibition of Cdc25C: possible involvement of PKN in the regulation of cell division. 
Proc Natl Acad Sci USA 98, 125–129 (2001).
 19. Metzger, E., Muller, J. M., Ferrari, S., Buettner, R. & Schule, R. A novel inducible transactivation domain in the androgen receptor: 
implications for PRK in prostate cancer. EMBO J. 22, 270–280 (2003).
 20. Leenders, F. et al. PKN3 is required for malignant prostate cell growth downstream of activated PI 3-kinase. EMBO J. 23, 3303–3313 (2004).
 21. Yasui, T. et al. Protein kinase N1, a cell inhibitor of Akt kinase, has a central role in quality control of germinal center formation. Proc 
Natl Acad Sci USA 109, 21022–21027 (2012).
 22. Oishi, K. et al. PKN regulates phospholipase D1 through direct interaction. J Biol Chem. 276, 18096–18101 (2001).
 23. Takahashi, M. et al. Regulation of a mitogen-activated protein kinase kinase kinase, MLTK by PKN. J Biochem. 133, 181–187 (2003).
 24. Yoshinaga, C., Mukai, H., Toshimori, M., Miyamoto, M. & Ono, Y. Mutational analysis of the regulatory mechanism of PKN: the 
regulatory region of PKN contains an arachidonic acid-sensitive autoinhibitory domain. J Biochem. 126, 475–484 (1999).
 25. Lakso, M. et al. Efficient in vivo manipulation of mouse genomic sequences at the zygote stage. Proc Natl Acad Sci USA 93, 
5860–5865 (1996).
 26. Balendran, A., Hare, G. R., Kieloch, A., Williams, M. R. & Alessi, D. R. Further evidence that 3-phosphoinositide-dependent protein 
kinase-1 (PDK1) is required for the stability and phosphorylation of protein kinase C (PKC) isoforms. FEBS Lett. 484, 217–223 (2000).
 27. Wick, M. J., Dong, L. Q., Riojas, R. A., Ramos, F. J. & Liu, F. Mechanism of phosphorylation of protein kinase B/Akt by a 
constitutively active 3-phosphoinositide-dependent protein kinase-1. J Biol Chem. 275, 40400–40406 (2000).
 28. Cyster, J. G. Chemokines, sphingosine-1-phosphate, and cell migration in secondary lymphoid organs. Annual review of 
immunology. 23, 127–159 (2005).
 29. Stein, J. V. & Nombela-Arrieta, C. Chemokine control of lymphocyte trafficking: a general overview. Immunology. 116, 1–12 (2005).
 30. Trepel, F. Number and Distribution of Lymphocytes in Man. A Critical Analysis. Klin Wschr (1974).
 31. Pabst, J. W. A. R. Distribution of lymphocyte subsets and natural killer cells in the human body. Clin Investig (1992).
 32. von Andrian, U. H. & Mempel, T. R. Homing and cellular traffic in lymph nodes. Nature reviews Immunology. 3, 867–878 (2003).
 33. Simmons, S. & Ishii, M. Sphingosine-1-phosphate: a master regulator of lymphocyte egress and immunity. Arch Immunol Ther Exp 
(Warsz). 62, 103–115 (2014).
www.nature.com/scientificreports/
13SCIentIfIC RepORtS | 7: 7663  | DOI:10.1038/s41598-017-07936-9
 34. Lo, C. G., Xu, Y., Proia, R. L. & Cyster, J. G. Cyclical modulation of sphingosine-1-phosphate receptor 1 surface expression during 
lymphocyte recirculation and relationship to lymphoid organ transit. J Exp Med. 201, 291–301 (2005).
 35. Schwab, S. R. et al. Lymphocyte sequestration through S1P lyase inhibition and disruption of S1P gradients. Science. 309, 1735–1739 
(2005).
 36. Pappu, R. et al. Promotion of lymphocyte egress into blood and lymph by distinct sources of sphingosine-1-phosphate. Science. 316, 
295–298 (2007).
 37. Matloubian, M. et al. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature. 427, 
355–360 (2004).
 38. Allende, M. L. et al. S1P1 receptor expression regulates emergence of NKT cells in peripheral tissues. Faseb j. 22, 307–315 (2008).
 39. Cinamon, G. et al. Sphingosine 1-phosphate receptor 1 promotes B cell localization in the splenic marginal zone. Nat Immunol. 5, 
713–720 (2004).
 40. Pham, T. H., Okada, T., Matloubian, M., Lo, C. G. & Cyster, J. G. S1P1 receptor signaling overrides retention mediated by G alpha 
i-coupled receptors to promote T cell egress. Immunity. 28, 122–133 (2008).
 41. Oo, M. L. et al. Immunosuppressive and anti-angiogenic sphingosine 1-phosphate receptor-1 agonists induce ubiquitinylation and 
proteasomal degradation of the receptor. J Biol Chem. 282, 9082–9089 (2007).
 42. Chiba, K. et al. FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of 
lymphocyte homing in rats. I. FTY720 selectively decreases the number of circulating mature lymphocytes by acceleration of 
lymphocyte homing. J Immunol. 160, 5037–5044 (1998).
 43. Mandala, S. et al. Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science. 296, 346–349 (2002).
 44. Luo, Z. J., Tanaka, T., Kimura, F. & Miyasaka, M. Analysis of the mode of action of a novel immunosuppressant FTY720 in mice. 
Immunopharmacology. 41, 199–207 (1999).
 45. Allende, M. L., Dreier, J. L., Mandala, S. & Proia, R. L. Expression of the sphingosine 1-phosphate receptor, S1P1, on T-cells controls 
thymic emigration. J Biol Chem. 279, 15396–15401 (2004).
 46. Yagi, H. et al. Immunosuppressant FTY720 inhibits thymocyte emigration. Eur J Immunol. 30, 1435–1444 (2000).
 47. Green, J. A. et al. The sphingosine 1-phosphate receptor S1P(2) maintains the homeostasis of germinal center B cells and promotes 
niche confinement. Nat Immunol. 12, 672–680 (2011).
 48. Moriyama, S. et al. Sphingosine-1-phosphate receptor 2 is critical for follicular helper T cell retention in germinal centers. J Exp Med. 
211, 1297–1305 (2014).
 49. O’Sullivan, A. G., Mulvaney, E. P., Hyland, P. B. & Kinsella, B. T. Protein kinase C-related kinase 1 and 2 play an essential role in 
thromboxane-mediated neoplastic responses in prostate cancer. Oncotarget (2015).
 50. O’Sullivan, A. G., Mulvaney, E. P. & Kinsella, B. T. Regulation of Protein Kinase C-related Kinase (PRK) signalling by the TPα and 
TPβ isoforms of the human Thromboxane A2 receptor: Implications for Thromboxane- and Androgen- dependent Neoplastic and 
Epigenetic Responses in Prostate Cancer. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease (2017).
 51. Turner, E. C. et al. Identification of an interaction between the TP&alpha; and TP{beta} isoforms of the human thromboxane A2 
receptor with protein kinase C-related kinase (PRK) 1. Implications for prostate cancer. J Biol Chem (2011).
 52. Jilg, C. A. et al. PRK1/PKN1 controls migration and metastasis of androgen-independent prostate cancer cells. Oncotarget (2014).
 53. Lachmann, S. et al. Regulatory domain selectivity in the cell-type specific PKN-dependence of cell migration. PLoS One. 6, e21732 (2011).
 54. Singh, N. K. et al. Protein Kinase N1 Is a Novel Substrate of NFATc1-mediated Cyclin D1-CDK6 Activity and Modulates Vascular 
Smooth Muscle Cell Division and Migration Leading to Inward Blood Vessel Wall Remodeling. J Biol Chem (2012).
 55. Stowers, L., Yelon, D., Berg, L. J. & Chant, J. Regulation of the polarization of T cells toward antigen-presenting cells by Ras-related 
GTPase CDC42. Proc Natl Acad Sci USA 92, 5027–5031 (1995).
 56. Sanchez-Madrid, F. & del Pozo, M. A. Leukocyte polarization in cell migration and immune interactions. EMBO J. 18, 501–511 (1999).
 57. del Pozo, M. A., Vicente-Manzanares, M., Tejedor, R., Serrador, J. M. & Sanchez-Madrid, F. Rho GTPases control migration and 
polarization of adhesion molecules and cytoskeletal ERM components in T lymphocytes. Eur J Immunol. 29, 3609–3620 (1999).
 58. Henderson, R. B. et al. A novel Rac-dependent checkpoint in B cell development controls entry into the splenic white pulp and cell 
survival. J Exp Med. 207, 837–853 (2010).
 59. Fukui, Y. et al. Haematopoietic cell-specific CDM family protein DOCK2 is essential for lymphocyte migration. Nature. 412, 
826–831 (2001).
 60. Montresor, A. et al. Comparative analysis of normal versus CLL B-lymphocytes reveals patient-specific variability in signaling 
mechanisms controlling LFA-1 activation by chemokines. Cancer Res. 69, 9281–9290 (2009).
 61. Rubtsov, A. et al. Lsc regulates marginal-zone B cell migration and adhesion and is required for the IgM T-dependent antibody 
response. Immunity. 23, 527–538 (2005).
 62. Nombela-Arrieta, C. et al. A central role for DOCK2 during interstitial lymphocyte motility and sphingosine-1-phosphate-mediated 
egress. J Exp Med. 204, 497–510 (2007).
 63. Eisenmann, K. M. et al. T cell responses in mammalian diaphanous-related formin mDia1 knock-out mice. J Biol Chem. 282, 
25152–25158 (2007).
 64. Sakata, D. et al. Impaired T lymphocyte trafficking in mice deficient in an actin-nucleating protein, mDia1. J Exp Med. 204, 
2031–2038 (2007).
 65. Kohler, J. et al. Lestaurtinib inhibits histone phosphorylation and androgen-dependent gene expression in prostate cancer cells. PLoS 
One. 7, e34973 (2012).
 66. Metzger, E. et al. Phosphorylation of histone H3 at threonine 11 establishes a novel chromatin mark for transcriptional regulation. 
Nat Cell Biol. 10, 53–60 (2008).
 67. Fukaya, M. et al. Abundant distribution of TARP gamma-8 in synaptic and extrasynaptic surface of hippocampal neurons and its 
major role in AMPA receptor expression on spines and dendrites. Eur J Neurosci. 24, 2177–2190 (2006).
 68. Mishina, M. & Sakimura, K. Conditional gene targeting on the pure C57BL/6 genetic background. Neurosci Res. 58, 105–112 (2007).
 69. Mukai, H. et al. Translocation of PKN from the cytosol to the nucleus induced by stresses. Proc Natl Acad Sci USA 93, 10195–10199 (1996).
 70. Mukai, H. et al. PKN3 is the major regulator of angiogenesis and tumor metastasis in mice. Sci Rep. 6, 18979 (2016).
 71. Matsuo, K. et al. CCR4 is critically involved in effective antitumor immunity in mice bearing intradermal B16 melanoma. Cancer 
Lett. 378, 16–22 (2016).
Acknowledgements
We thank Kimi Araki (Kumamoto university) for providing us with EGFP transgenic mouse. We thank the 
following people for helpful experiments and discussion with this work: Akimasa Nishimoto, Ayako Kita, Daiji 
Sakata, Hiroki Satooka, Kazuhiro Shiga, Mona Mehruba, Rie Natsume, Ryohei Sasaki, Siddique Salman Mahmud, 
Yoshitaka Ono, Yumi Fujimoto, and staffs of Japan Mouse Clinic. We would like to thank Editage for English 
language editing. This work was supported by research grants from the Ministry of Education, Culture, Sports, 
Science and Technology, Japan, and by the MEXT-Supported Program for the Strategic Research Foundation at 
Private Universities, 2014–2018 (S1411037).
www.nature.com/scientificreports/
1 4SCIentIfIC RepORtS | 7: 7663  | DOI:10.1038/s41598-017-07936-9
Author Contributions
M.A., K.S., and H.M. generated PKN1[T778A] mouse line. R.M., A.N., A.H., K.K., S.D., T.H., K.M., T.N., R.Satoh, 
R.Sugiura., S.W., H.O., S.K., and H.M. carried out blood cell experiments and analyses. H.M. designed the project 
and wrote the manuscript. All authors reviewed the manuscript.
Additional Information
Supplementary information accompanies this paper at doi:10.1038/s41598-017-07936-9
Competing Interests: The authors declare that they have no competing interests.
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Cre-
ative Commons license, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons license and your intended use is not per-
mitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the 
copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
 
© The Author(s) 2017
